Testosterone Therapy for Late-Onset Hypogonadism Improves Erectile Function: A Systematic Review and Meta-Analysis

Area of Science:

• Endocrinology
• Urology
• Men's Health

Background:

• Late-onset hypogonadism affects erectile function.
• Testosterone therapy (TTh) is a potential treatment.
• Evidence on TTh efficacy for erectile function requires systematic review.

Approach:

• Systematic review and meta-analysis of randomized controlled trials (RCTs) published since 2007.
• Included studies assessed erectile function using the International Index of Erectile Function-Erectile Function Domain (IIEF-EFD).
• Analyzed data from 18 RCTs (systematic review) and 6 RCTs (meta-analysis) involving 1,458 patients.

Key Points:

• TTh significantly improved IIEF-EFD scores compared to placebo (mean difference 1.86, p < 0.0001).
• Improvements were notable with testosterone gel, treatment exceeding 30 weeks, and in patients without diabetes mellitus or metabolic syndrome.
• Meta-analysis included 6 studies with 1,458 patients.

Conclusions:

• Testosterone therapy effectively enhances erectile function in hypogonadal men.
• Optimal outcomes observed with specific formulations (testosterone gel), treatment duration (>30 weeks), and in healthier patient subgroups.
• TTh offers a viable therapeutic option for improving sexual health in men with hypogonadism.